E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
- Biotech or pharma, therapeutic R&D
EnitiateBio is committed to the development of inovative drugs for autoimmune diseases such as atopic dermatitis, Prurigo nodularis and plaque psoriasis , through independent research and development, and strategic collaborations, to address unmet medical needs and to improve the quality of human life.QY201(Tables,JAK1/TKY2 inhibitor，Phase3) and QY211(Gel,JAK1/TKY2 inhibitor，Phase1) which are the first class of innovative drugs with global patents developed by the company, are in the clinical trial stage, and have been approved for more than 30 clinical approvals and more than 10 indications.
We are looking forward to working with academic institutions, biotech companies and pharmaceutical companies around the world to discuss Ex - china/Global right out - license.
If you or any member of your team are interested in discussing this further, please feel free to contact us!
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}